Compare Danaher Corporation (DHR) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Enbridge Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Enbridge Inc trades at $46.6 (market cap $103.38B). The key difference: Danaher Corporation is the larger of the two by market cap, and Enbridge Inc pays the higher dividend (6.02%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Enbridge Inc for 91 Days on average.
| DHR | ENB | |
|---|---|---|
Market Cap | $152.87B | $103.38B |
Volume | 5,228,698 | 3,684,305 |
Sector | Health | Energy |
52-Week High | $242.05 | $58.04 |
52-Week Low | $161.91 | $45.23 |
Typical Hold Time | 69 Days | 91 Days |
Enterprise Value | $175.08B | $185.39B |
Dividend Yield | 0.74% | 6.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
ENB trades at $46.54, up 1.42% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $65.19B in 2025, and the dividend yield is attractive at approximately 6% based on the recent $0.97 payout. Analyst consensus is mixed with a $61.63 price target, indicating potential upside from current levels.
The outlook for ENB is supported by stable cash flows and a secured project backlog, but risks include high debt levels and sensitivity to interest rates. Investment opportunity lies in the dividend income and valuation discount to analyst targets, though investors face headwinds from energy market volatility and rising leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
